Scopus Biopharma

Scopus Biopharma Asset Turnover

Asset Turnover Ratio of Scopus Biopharma (SCPS) as of Nov 3, 2026.

Asset Turnover

0.00

Last updated:

Asset Turnover Ratio of Scopus Biopharma is 2022 0.00 . Asset Turnover Ratio of Scopus Biopharma was 2021 0.00 . It decreases by % lower compared to the previous year.

The Scopus Biopharma Asset Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Asset Turnover
Date
Asset Turnover
Jan 1, 2018
0.00 USD
Jan 1, 2019
0.00 USD
Jan 1, 2020
0.00 USD
Jan 1, 2021
0.00 USD
Jan 1, 2022
0.00 USD
The Scopus Biopharma Asset Turnover history
YEARAsset TurnoverYoY
0.00—
0.00—
0.00—
0.00—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Scopus Biopharma Stock analysis

What does Scopus Biopharma do? Scopus Biopharma Inc develops therapeutics targeting diseases with unmet medical needs, focusing on immuno-oncology programs. The company's Duet Platform utilizes bifunctional oligonucleotides to activate antigen-presenting cells and alleviate tumor immunosuppression. DUET-01 is in development for relapsed or refractory B-cell non-Hodgkin lymphoma, while DUET-02 targets solid tumors like prostate or kidney cancers through systemic delivery. The firm's products are developed for clinical trials and potential future commercialization. Scopus Biopharma's revenue streams are not disclosed in the business description, but the company is developing its Duet Platform products for potential licensing or partnership agreements. The immuno-oncology focus and bifunctional oligonucleotide platform represent the core of the company's product pipeline. The company's products target specific cancer types with unmet medical needs, aiming to jump-start T cell-mediated immune responses. The company's development pipeline includes DUET-01 for B-cell non-Hodgkin lymphoma and DUET-02 for solid tumors. The Duet Platform's three bifunctional oligonucleotides (DUET-01, DUET-02, DUET-03) form the foundation of its therapeutic approach. The firm is developing these products for potential commercialization after successful clinical trials and regulatory approvals. Scopus Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Scopus Biopharma stock

On Eulerpool you can find the complete historical development of Asset Turnover Ratio Scopus Biopharma since 2006 – with annual values, charts, and detailed analysis.

Asset turnover measures how efficiently a company uses its assets to generate revenue. Higher ratios indicate more efficient asset utilization.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Asset Turnover Ratio's Scopus Biopharma with sector peers and the industry average to assess whether it is attractive.

To evaluate Asset Turnover Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Asset Turnover Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Scopus Biopharma

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Scopus Biopharma